PE Tech Report


Like this article?

Sign up to our free newsletter

Shore Capital Partners sells ClearPath Diagnostics

Shore Capital Partners, a healthcare-focused private equity firm, has sold ClearPath Diagnostics, a provider of laboratory diagnostic services in the north-eastern US, to Laboratory Corporation of America (LabCorp).

Shore Capital partnered with ClearPath’s founding pathologists, Dr Michael Jozefczyk and Dr Michael Mazur, to drive the company’s expansion beyond the local Syracuse, New York market. 
Together, Shore Capital and ClearPath executed a growth strategy that extended the company’s geographic reach to four states and expanded the service menu to include new cutting-edge tests.
The growth was driven by organic initiatives as ClearPath expanded the sales force from one professional to a team of nine highly trained business development experts and implemented LEAN processes that ensured best-in-class turnaround times.
Jozefczyk says: “Shore Capital was the perfect partner to guide ClearPath through a period of transformational growth. Their commitment to clinical quality combined with deep business development expertise allowed ClearPath to thrive during a difficult period in the diagnostic lab industry. With Shore Capital’s assistance, we successfully expanded into three new states across the Northeast and our revenue growth outpaced industry averages by more than 10x. The commitment to growth combined with sophisticated metric management techniques allowed us to become the leading independent provider of cancer testing services in the Northeast.”
“The success of this partnership is a testament to the hard work of the ClearPath team and further validation of Shore Capital's model of partnering with influential clinicians to grow local businesses into regional leaders,” says Justin Ishbia, managing partner of Shore Capital and chairman of ClearPath Diagnostics. “We are pleased with the outcome of this partnership and believe that ClearPath is well positioned to continue growing as a leader in the field of cancer diagnostics.”
“LabCorp is excited to both continue its commitment to the upstate New York medical communities and for the potential to grow career opportunities in the entire region over time,” says William Haas, LabCorp senior vice president and co-leader of LabCorp Diagnostics. “The combination of LabCorp’s comprehensive women’s health service offering coupled with the local expertise of the ClearPath professional team will be an unmatched blend of value and quality to our Obstetric and Gynecologic customers and patients."
The transaction closed on 3 October 2016. Terms of the transaction have not been disclosed. Winston & Strawn served as legal adviser to ClearPath on the transaction.

Like this article? Sign up to our free newsletter